Why the study?
Resistant hypertension accounts for roughly one in six hypertension cases and is associated with severe morbidity and mortality, yet no endothelin receptor antagonist has been marketed for it despite endothelin's potential role in its pathology.
Does aprocitentan reduce systolic and diastolic blood pressure in patients with resistant hypertension?
Does aprocitentan reduce systolic and diastolic blood pressure in patients with resistant hypertension?
Aprocitentan is a promising new endothelin receptor antagonist in development that may provide a novel therapeutic option for resistant hypertension.
Resistant hypertension (RH) is the state of uncontrolled blood pressure in the face of ostensibly optimal pharmacological intervention. It accounts for roughly one in six cases of hypertension, and is associated with more severe morbidity and mortality outcomes than is non-RH. The prevalence of RH implies a currently unmanaged pathology, which may involve the potent vasoconstrictor endothelin. Several endothelin receptor antagonists are currently marketed for pulmonary arterial hypertension, but none so far has been marketed for RH. Aprocitentan is currently in development, an endothelin receptor antagonist that effectively produces clinically significant and sustained decreases in systolic and diastolic blood pressure in the setting of RH.
No takes yet. Share an insight, caveat, or question.
Airo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: